Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication,...

Full description

Bibliographic Details
Main Authors: Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González-Martín
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Rucaparib
Recurrent ovarian cancer
Maintenance
Treatment
PARP inhibitor
Online Access:https://doi.org/10.1186/s12885-022-10191-5

Similar Items

Similar Items